#ESMO26 | HARMONi-GI1| Presidential Session-2

In 1L advanced biliary tract cancer, ivonescimab + chemo vs durvalumab + chemo:

🔹 OS: 14.9 vs 12.1 mo
🔹 PFS: 8.4 vs 5.8 mo
🔹 ORR: 53.8% vs 32.5%

A clinically meaningful improvement in OS and PFS against an active SoC comparator